Mobia Medical (NASDAQ:MOBI) Given “Buy” Rating at BTIG Research

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They currently have a $19.00 target price on the stock. BTIG Research’s price objective suggests a potential upside of 109.48% from the company’s previous close.

MOBI has been the subject of a number of other reports. JPMorgan Chase & Co. raised their price objective on Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Weiss Ratings assumed coverage on Mobia Medical in a report on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mobia Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Trading Up 3.0%

NASDAQ MOBI traded up $0.26 during trading on Tuesday, reaching $9.07. 33,483 shares of the company’s stock were exchanged, compared to its average volume of 173,179. Mobia Medical has a fifty-two week low of $8.03 and a fifty-two week high of $15.29. The company has a market capitalization of $301.94 million and a price-to-earnings ratio of -0.45. The company has a quick ratio of 12.80, a current ratio of 13.28 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average price of $10.21.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. The business’s revenue for the quarter was up 102.4% on a year-over-year basis. Equities analysts forecast that Mobia Medical will post -2.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Casey Tansey acquired 16,441 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $12.07 per share, for a total transaction of $198,442.87. Following the completion of the acquisition, the director owned 318,332 shares in the company, valued at approximately $3,842,267.24. The trade was a 5.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 87,000 shares of company stock worth $1,016,367 in the last ninety days.

Institutional Trading of Mobia Medical

Several hedge funds and other institutional investors have recently modified their holdings of MOBI. State Street Corp purchased a new stake in shares of Mobia Medical during the second quarter worth $735,000. Citadel Advisors LLC purchased a new stake in shares of Mobia Medical during the second quarter worth $670,000. Finally, Readystate Asset Management LP purchased a new stake in shares of Mobia Medical during the second quarter worth $134,000.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.